The most common grade 3 AEs (occurring in ≥10% of patients) in the dovitinib vs placebo arms were hypertension (21.3% vs 6.0%), diarrhea (14.9% vs 4.0%), alanine aminotransferase increase (14.9% vs 2.0%), fatigue (12.8% vs 2.0%), blood alkaline phosphatase increase (12.8% vs 0%), and γ-glutamyltransferase increase (10.6% vs 6.0%). This evidence concerns the gene GPT and hypertensive disorder.